Good Q4. Credit Neutral. Diabetes spin-off confirmed.
• Q4 sales $8.93bn +5.4% organic. Slightly above estimates.
• Q4 GAAP Op Profit $1.44bn with 16.1% margin (up 380bps).
• Full Year $33.54bn sales +4.9% organic.
• Full Year margin 17.8% up 190bps.
• Diabetes revenue $2.755bn. Company confirms that this will be spun-off within 18 months.
• Guidance: 4.8%-5.1% organic growth. EPS to grow 4% ex-tariffs. $5.50-$5.60 range is below $5.83 estimates.
• €2.5bn EURO bonds mature in 2025. Issued €3bn in May ’24.
Find more articles and bullets on these widgets:
The US dollar sell off has continued through today’s APAC sell off with the USD BBDXY now down 0.8% and close to its intraday low, as confidence in the US as a safe haven wanes following uncertainty over its trade policy and now President Trump’s interference with the Fed. Unusually this has coincided with US equity futures deeply in negative territory. Flight-to-quality flows have seen the yen, euro and Swiss franc all strengthen by at least 1% against the greenback but also kiwi, which is usually risk sensitive.
Kiwi has been one of the strongest performers in today’s US dollar sell off. NZDUSD is up 1.2% to 0.6006, above 60c for the first time since November. It reached a high of 0.6007. With US equity futures selling off, Aussie has underperformed much of the G10 but is still stronger on the day. The BBDXY USD index is down 0.8%.